ChemoCentryx Inc. (NASDAQ:CCXI) has a beta of 1.60. The stock’s Relative Strength Index (RSI) is 15.99, with weekly volatility at 10.22% and ATR at 4.03. The CCXI stock’s 52-week price range has touched low of $9.55 and a $70.29 high. Its shares traded higher over the last trading session, gaining 4.71% on 05/14/21. The shares fell to a low of $9.92 before closing at $10.44. Intraday shares traded counted 3.06 million, which was -39.52% lower than its 30-day average trading volume of 2.19M. CCXI’s previous close was $9.97 while the outstanding shares total 69.61M.
Investors have identified the Biotechnology company ChemoCentryx Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $695.41 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
ChemoCentryx Inc. (CCXI) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CCXI, the company has in raw cash 68.55 million on their books with 9.61 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 390.64 million total, with 54.73 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -1.89 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CCXI sounds very interesting.
Is the stock of CCXI attractive?
In related news, EVP, Chief Operating Officer, Butt Tausif bought 10,870 shares of the company’s stock in a transaction that recorded on May 07. The purchase was performed at an average price of 11.06, for a total value of 120,241. As the purchase deal closes, the Director, Parker Geoffrey M. now sold 30,000 shares of the company’s stock, valued at 1,691,468. Also, Director, Parker Geoffrey M. sold 1,910 shares of the company’s stock in a deal that was recorded on Mar 04. The shares were cost at an average price of 60.20 per share, with a total market value of 114,980. Following this completion of disposal, the Director, Edwards Thomas A. now holds 1,100 shares of the company’s stock, valued at 77,063. In the last 6 months, insiders have changed their ownership in shares of company stock by 3.90%.